GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » Total Operating Expense

GlaxoSmithKline Pakistan (KAR:GLAXO) Total Operating Expense : ₨5,655 Mil (TTM As of Mar. 2025)


View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan Total Operating Expense?

GlaxoSmithKline Pakistan's Total Operating Expense for the three months ended in Mar. 2025 was ₨1,737 Mil. GlaxoSmithKline Pakistan's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was ₨5,655 Mil.


GlaxoSmithKline Pakistan Total Operating Expense Historical Data

The historical data trend for GlaxoSmithKline Pakistan's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pakistan Total Operating Expense Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,960.32 3,029.94 2,393.19 1,626.95 5,245.00

GlaxoSmithKline Pakistan Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,326.52 1,354.90 1,382.53 1,181.06 1,736.80

GlaxoSmithKline Pakistan Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨5,655 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlaxoSmithKline Pakistan Total Operating Expense Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pakistan's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Pakistan Business Description

Traded in Other Exchanges
N/A
Address
35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines